Mirati Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
3545 Cray Court, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 6, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 695 % -32.4%
Quick Ratio 6.35 %
Debt-to-equity 21.1 % +46.3%
Return On Equity -82.2 % -36%
Return On Assets -67.8 % -28.5%
Operating Margin -2K % +68.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.1M shares +21.8%
Common Stock, Shares, Outstanding 70.1M shares +21.8%
Entity Public Float 3.7B USD -50%
Common Stock, Value, Issued 70K USD +20.7%
Weighted Average Number of Shares Outstanding, Basic 65M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 65M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 38.2M USD +224%
Research and Development Expense 507M USD -6.86%
General and Administrative Expense 213M USD +79.4%
Operating Income (Loss) -765M USD -2.68%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162M USD +6.58%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -726M USD +1.64%
Earnings Per Share, Basic -12.2 USD/shares +9.01%
Earnings Per Share, Diluted -12.2 USD/shares +9.01%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 259M USD -13.4%
Marketable Securities, Current 718M USD -20.4%
Accounts Receivable, after Allowance for Credit Loss, Current 14.7M USD
Inventory, Net 20.2M USD
Assets, Current 1.04B USD -15.5%
Property, Plant and Equipment, Net 16M USD -10.4%
Operating Lease, Right-of-Use Asset 35.1M USD -3.82%
Other Assets, Noncurrent 24.8M USD +17.9%
Assets 1.13B USD -13.3%
Employee-related Liabilities, Current 34.5M USD +20.8%
Accrued Liabilities, Current 99.4M USD -7.55%
Liabilities, Current 137M USD +8.18%
Operating Lease, Liability, Noncurrent 42.2M USD -4.29%
Other Liabilities, Noncurrent 3.66M USD +24.1%
Liabilities 183M USD +5.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.55M USD +74.7%
Retained Earnings (Accumulated Deficit) -2.98B USD -32.3%
Stockholders' Equity Attributable to Parent 946M USD -16.2%
Liabilities and Equity 1.13B USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -190M USD -18.5%
Net Cash Provided by (Used in) Financing Activities 1.73M USD -31.7%
Net Cash Provided by (Used in) Investing Activities 195M USD +294%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 70.1M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.67M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 259M USD -13.4%
Deferred Tax Assets, Valuation Allowance 620M USD +47.2%
Deferred Tax Assets, Gross 628M USD +46.4%
Operating Lease, Liability 51.5M USD +12.2%
Depreciation 629K USD +114%
Payments to Acquire Property, Plant, and Equipment 269K USD -76.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -721M USD +4.3%
Property, Plant and Equipment, Gross 23M USD +23.5%
Operating Lease, Liability, Current 8.02M USD +11.9%
Deferred Tax Assets, Operating Loss Carryforwards 255M USD -14.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 3.92B USD +15.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1M USD
Depreciation, Depletion and Amortization 1.08M USD +70.9%
Deferred Tax Assets, Net of Valuation Allowance 8.23M USD +4.04%
Share-based Payment Arrangement, Expense 193M USD +21.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%